Last reviewed · How we verify

Duloxetine Hydrochloride (HCI)

Eli Lilly and Company · Phase 3 active Small molecule

Duloxetine Hydrochloride (HCI) is a Serotonin-norepinephrine reuptake inhibitor (SNRI) Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 3 development for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain. Also known as: LY248686, Cymbalta.

Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.

Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. Used for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain.

At a glance

Generic nameDuloxetine Hydrochloride (HCI)
Also known asLY248686, Cymbalta
SponsorEli Lilly and Company
Drug classSerotonin-norepinephrine reuptake inhibitor (SNRI)
TargetSerotonin transporter (SERT); Norepinephrine transporter (NET)
ModalitySmall molecule
Therapeutic areaPsychiatry, Neurology, Pain Management
PhasePhase 3

Mechanism of action

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This dual mechanism is thought to enhance mood regulation and pain signaling modulation. The drug is used to treat depression, anxiety disorders, and chronic pain conditions including diabetic peripheral neuropathic pain and fibromyalgia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Duloxetine Hydrochloride (HCI)

What is Duloxetine Hydrochloride (HCI)?

Duloxetine Hydrochloride (HCI) is a Serotonin-norepinephrine reuptake inhibitor (SNRI) drug developed by Eli Lilly and Company, indicated for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain.

How does Duloxetine Hydrochloride (HCI) work?

Duloxetine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.

What is Duloxetine Hydrochloride (HCI) used for?

Duloxetine Hydrochloride (HCI) is indicated for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain, Fibromyalgia, Chronic musculoskeletal pain.

Who makes Duloxetine Hydrochloride (HCI)?

Duloxetine Hydrochloride (HCI) is developed by Eli Lilly and Company (see full Eli Lilly and Company pipeline at /company/eli-lilly).

Is Duloxetine Hydrochloride (HCI) also known as anything else?

Duloxetine Hydrochloride (HCI) is also known as LY248686, Cymbalta.

What drug class is Duloxetine Hydrochloride (HCI) in?

Duloxetine Hydrochloride (HCI) belongs to the Serotonin-norepinephrine reuptake inhibitor (SNRI) class. See all Serotonin-norepinephrine reuptake inhibitor (SNRI) drugs at /class/serotonin-norepinephrine-reuptake-inhibitor-snri.

What development phase is Duloxetine Hydrochloride (HCI) in?

Duloxetine Hydrochloride (HCI) is in Phase 3.

What are the side effects of Duloxetine Hydrochloride (HCI)?

Common side effects of Duloxetine Hydrochloride (HCI) include Nausea, Dizziness, Somnolence, Dry mouth, Fatigue, Constipation.

What does Duloxetine Hydrochloride (HCI) target?

Duloxetine Hydrochloride (HCI) targets Serotonin transporter (SERT); Norepinephrine transporter (NET) and is a Serotonin-norepinephrine reuptake inhibitor (SNRI).

Related